fMRI Cholinergic Mechanisms in Schizophrenia

US Department of Veterans Affairs1 site in 1 country40 target enrollmentOctober 2008

ConditionsSchizophrenia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Schizophrenia
Sponsor: US Department of Veterans Affairs
Enrollment: 40
Locations: 1
Primary Endpoint: Neuronal Response During Sensory Gating
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.

Detailed Description

This study will use functional magnetic resonance imaging (fMRI) to study patients treated with risperidone, a commonly used neuroleptic that does not improves sensory gating, to those treated with clozapine to determine which brain areas are involved in clozapine's normalization of sensory gating in schizophrenia.

Registry

clinicaltrials.gov

Start Date

October 2008

End Date

December 2011

Last Updated

10 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

US Department of Veterans Affairs

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Diagnosis of schizophrenia
•age 18-60 yrs

Exclusion Criteria

•claustrophobia
•weight \> 250 lbs
•metal in body other than dental fillings

Outcomes

Primary Outcomes

Neuronal Response During Sensory Gating

Time Frame: Immediate

Neuronal response (blood oxygenation level dependent functional magnetic resonance imaging signal, relative to the global mean) during sensory gating. Sensory gating is defined as the process of filtering out unnecessary environmental stimuli.